Advertisement

Halofenate: Effectiveness of two dosage forms and two dose schedules

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Twenty patients with consistent hyperuricemia and hypertriglyceridemia were randomly allocated into treatment groups receiving 1 g of halofenate daily as tablets (1000 mg once daily) or capsules (500 mg twice daily) for 4 weeks. Serum uric acid levels were significantly reduced within 1 week. Triglyceride levels also fell promptly, but the reductions were less uniform and less pronounced. The effect on cholesterol was minimal in the limited time of the study.
      Asymptomatic decreases in serum bilirubin, albumin, and protein bound iodine occurred consistently. Although a few patients had serum creatine phosphokinase elevations, none were symptomatic.
      In those patients whose pretreatment triglyceride levels were above 250mg/100 ml there was a linear correlation between the percentage reduction of triglyceride and the dose of halofenate. No differences between tablets and capsules, or in dosage frequency, were discerned.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Jain A.
        • Ryan J.R.
        • Hague D.
        • McMahon F.G.
        The effect of MK-185 on some aspects of uric acid metabolism.
        Clin. Pharmacol. Therap. 1970; 11: 551
        • Morgan J.P.
        • Bianchine J.R.
        • Tah-Hsiung Hsu
        • Margolis S.
        Hypolipidemic, uricosuric, and thyroxine-displacing effects of MK-185 (halofenate).
        Clin. Pharmacol. Therap. 1971; 12: 517
        • Fredrickson D.S.
        • Lees R.S.
        A system for phenotyping hyperlipoproteinema.
        Circulation. 1965; 31: 321
        • Hutchison J.C.
        • Wilkinson W.H.
        The uricosuric action of halofenate (MK-185) in patients with hyperuricemia or uncomplicated primary gout and hyperlipidemia.
        Atherosclerosis. 1973; 18: 353
        • Ramsdell C.M.
        • Kelley H.N.
        The clinical significance of hypouricemia.
        Ann. Internal Med. 1973; 78: 329